Discussion  by unknown
Navia et al Acquired Cardiovascular Diseaseaortic valve repair/replacement, coronary artery bypass
grafting, surgical ablation for atrial fibrillationA
C
DDiscussion
Dr Farzan Filsoufi (New York, NY). I have a disclosure; I am
a speaker for Edwards Lifesciences. First, I congratulate you, Dr
Navia, for this important study, which includes a large cohort of pa-
tients. I would also like to remind our audience that the first part of
this study, from 1990 to 1999, which included 800 patients, was
presented by Dr McCarthy at the Eighty-third Annual Meeting of
The American Association for Thoracic Surgery and published in
this Journal in March 2004.
I think the main conclusions of your work, with which I agree, is
that the remodeling annuloplastywith either aCarpentier&Edwards
semirigid ring or an MC3 ring (Edwards Lifesciences) is superior to
other techniques such as suture annuloplasty and flexible band annu-
loplasty, and, as Dr Tirone David has shown, it has been associated
with an improved long-term survival. I think the second important
conclusion is that the palliative techniques, such as edge-to-edge re-
pair technique, do not play any role in further improving outcome
after a remodeling annuloplasty. Finally, although remodeling annu-
loplasty is superior to other techniques, it is associated with an early
failure rate of about 10% to 15% in your study. This has not been our
experience at Mount Sinai Medical Center. Therefore, most of my
discussion will be directed to our understanding the mechanism of
this early failure.
First, as you know, most patients with functional TR have iso-
lated annular dilatation, type I dysfunction, or restricted leaflet mo-
tion, type IIIb dysfunction, with associated annular dilatation.
Have you observed any difference of outcome, particularly with
respect to early or late failure, between these 2 groups of patients,
and have you been able to identify any risk factors such as RV dys-
function, enlargement, or pulmonary hypertension for this early
failure?
Dr Navia. Thank you for your comments. We have not found
any distinctions about this pathologic study in terms of regurgita-
tion. In terms of the treatment, I agree with you; I think the best be-
haved ring is the rigid ring, and then also the 3-dimensional rings
behaved the same. We have not observed any differences of early
or late TR between these 2 groups.
Dr Filsoufi. My second question is regarding the ring sizing.
What criteria do you use for ring sizing and do you make any dif-
ference in patients with type A versus type IIIb, particularly with
regard to undersizing?
Dr Navia. That is a good question. We do not make any different
criteria for sizing between typeA and type IIIb of theCarpentier clas-
sification. We usually undersize the ring. We usually size by the sur-
face area of the septal leaflet and, based on that, we place the ring; the
choice of the specific ring depends on the surgeon preference.
Dr Filsoufi. In the article published in 2004 by Patrick McCar-
thy, which reported your cohort again from 1990 to 1999, the ma-
jority of patients who underwent a semirigid annuloplasty had
a size 32 mm or 34 mm, and they were not undersized. In the dis-
cussion of this same manuscript, Dr McCarthy mentioned that
undersizing was commonly performed, at least in patients with car-
diomyopathy, during the second part of your study period. Do youThe Journal of Thoracic and Carhave any data comparing patients who have a 2-size remodeling an-
nuloplasty versus an undersized remodeling annuloplasty?
Dr Navia. No, we do not have any data for that.
Dr Filsoufi. My fourth question is this: To prevent the recur-
rence of early TR, do you use any adjunctive procedures such as
anterior leaflet patch extension, as suggested by Gilles Dreyfus?
DrNavia. This is a very important issue.We do not use any kind
of leaflet extension with bovine or autologous pericardium, but I
think we need to start thinking about new procedures. I do not think
the ring itself is completely effective in reducing TR completely.
The other component that we miss here is the ventricle, and we
need to start thinking of the subvalvular apparatus and the ventricle
geometry and which role they play on secondary TR in this popu-
lation. I think with just the ring itself, TR can be reduced but not
completely eliminated.
Dr Filsoufi. My final question is this: In the presence of recur-
rent 3þ to 4þTR early after the operation, how do you use this in-
formation?What is the percentage of patients who had reoperations
and what type of procedure do you perform?
Dr Navia. This is a very good question. The rate of 3þ to 4þTR
before discharge is very low, but when it happens, I think these pa-
tients need to return to the operating room. If the valve cannot be
repaired again, it must be replaced. We usually use a tissue valve.
I think it is safer to replace the valve than to send the patient
home with the risk that he or she will return with full right heart fail-
ure. Many of these patients (eg, 48% of our patients) require a reop-
eration, and this will be the third one; they have a very high risk of
morbidity and mortality—between 30% and 40%. Therefore, I think
if you have patients with 3þ to 4þTR before discharge, you have to
return them to the operating room before sending them home.
Dr Norberto De Vega (Malaga, Spain). I congratulate the au-
thors for such a good study. I have some comments and questions
for Dr Navia.
Nowadays, we do not have any problem with how to treat the tri-
cuspid valve. We always use a properly performed suture annulo-
plasty, but we think that it is completely different if it is
a rheumatic or a degenerative disease. In patients with rheumatic
disease, we do not think there is such a clear-cut difference as we
thought in the past among organic and functional regurgitation.
For the past 15 years, we have visually explored every tricuspid
valve of our patients with rheumatic mitral disease, and in most of
them, even in those without regurgitation at that time, we found
some subtle changes in the leaflets that probably progress with
the passing of time and are responsible for the TR that appears
late after left heart valve surgery. To avoid that, we have proposed
to fix the tricuspid annulus in every case to break the vicious circle
triggered by any degree of TR and in which annular dilatation plays
an essential role.
Do you agree that there is no clear-cut difference, in patients
with rheumatic disease, between functional and organic tricuspid
disease?
Second, when those patients come back late after mitral surgery
with isolated TR, do you have any clue to differentiate patients who
are going to benefit by an operation from the ones who will not?
Dr Navia. Thank you for the question, Dr De Vega. These cer-
tainly are 2 different patient groups. However, we analyzed your
technique in these 2 populations, rheumatic and degenerative.
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Dand both had the same rate of failure in our experience. Already,
24% of the patients have a recurrent 3þ to 4þTR at 5 years with
the De Vega technique.
Dr Tirone E. David (Toronto, Ontario, Canada). I enjoyed
your paper very much. Years ago, your cardiologists published
the importance of tethering of the tricuspid leaflets on the outcome
of tricuspid annuloplasty. They have been telling us that surgeons
are overlooking tethering of the anterior and posterior leaflets,
which is not mentioned in your study at all. Aren’t you talking to
your cardiologists? Why didn’t you address this issue when you
did an annuloplasty? I am saying that because I learned this from
your cardiologists, and since we introduced this concept in my op-
erating room, we have not had recurrent TR anymore if you look at
tethering before you do annuloplasty.
Dr Navia. That is a very good point. We have not taken a look
completely at the tethering effect in all the cases, so we do not
have a complete echocardiography result to give the data. Lately,
we are starting to get more perspective to see this distance of the teth-
ering and the unbalanced coaptation of the leaflets to be more proac-
tive and try to use new remodeling shaped rings. But I cannot give in
this presentation the real number of echocardiograms because we do
not have it. Usually, the echo we have mainly is grade of TR. It is
very difficult to quantify the leaflet moving and the leaflet coaptation.
Dr David. Are you asking the sonographer before the operation
what segment has tethering before you do an annuloplasty?
Dr Navia. Yes, we started doing more and more right after the
Yacoub paper, and our papers also showed that the deepness of
the coaptation owing to the tethering of the tricuspid leaflet creates
more recurrence of TR over time. That is a very important issue.
Otherwise, we are looking right now at different concentric changes
of the geometry of the RV, mainly the trabecular septomarginalis,
that pulls the RV free wall, changes the anterior papillary muscle,
and creates anterior leaflet tethering. We are now trying to
find new techniques, because we know that the ring alone is insuf-
ficient to completely eliminate the TR secondary to left-sided valve.
Without question, I cannot agree more with you; we are looking for
that.
Dr Richard J. Shemin (Los Angeles, Calif). One of the powers
of this study is the large number of patients. However, every sur-1482 The Journal of Thoracic and Cardiovascular Surgeon has in his or her armamentarium awhole variety of techniques,
and therefore there is bias. Very often you can do a propensity score
to try to level the field to be sure that the decision–making of the in-
dividual surgeon who has all these techniques at his or her disposal
is kind of eliminated. Did you think of doing that?
Dr Navia. That is a reasonable question. That could be the best
way to analyze this study. However, unfortunately it is a long pro-
cedure of 18 years with different surgeon preferences, so we did
only an observational cohort study. The next step would be to di-
rectly focus on propensity score analysis.
Dr Patrick M. McCarthy (Chicago, Ill). By way of disclosure,
I am the inventor of the Edwards MC3 ring.
Dr Navia, it appeared that about 15% of the patients had a perma-
nent pacemaker before surgery. In the study that we had reported
before, that was one of the major risk factors for failure. How do
you manage that in this series? Is there a standardized approach
now for how to deal with permanent pacing wires?
Dr Navia. Thank you, Dr McCarthy. We found the same situa-
tion—15% of the patients had a previous pacemaker. This is one of
the high risk factors of recurrent TR, because the pacemaker leads
can erode or perforate the leaflet and sometimes become stuck to
the leaflet, impeding free leaflet movement and creating TR. We
manage this by removing the wires through the tricuspid valve
and then placing permanent epicardial leads on the RV. I think
that is the best way to eliminate the potential problems of recur-
rence of TR or cause a negative effect on the tricuspid valve repair
technique.
Dr David H. Adams (New York, NY).Dr Navia, can I ask you to
speculate on the mechanism of failure with the flexible ring? In the
mitral position, we know the intertrigonal distance dilates in heart
failure and dilated cardiomyopathy, but I am not aware of any ev-
idence that the septum of the tricuspid annulus dilates in cardiomy-
opathy. Do you have any idea, any mechanism why you are seeing
recurrence of TR with flexible bands?
Dr Navia. I really do not know the intrinsic mechanism of fail-
ure of the flexible bands. Perhaps the flexible ring does not have
enough strength to maintain the new annular size and does not pre-
vent annular dilation as well as the rigid ring when the RV con-
tinues to remodel over time. That could be one of the reasons.gery c June 2010
